Artificial intelligence continues to transform drug discovery in the pharmaceutical and biotech industries. Converge Bio, a startup based in Boston and Tel Aviv, has secured $25 million in a Series A funding round led by Bessemer Venture Partners, with support from executives at Meta, OpenAI, and Wiz.
Converge Bio specializes in accelerating drug development for pharma and biotech companies through the use of generative AI trained on molecular data. By integrating AI models into research workflows, the company aims to streamline the drug development process and bring new medications to market more efficiently.
The startup’s platform leverages generative models trained on DNA, RNA, and protein sequences to enhance various stages of drug development, from target identification to clinical trials. Converge Bio has already introduced three distinct AI systems focusing on antibody design, protein yield optimization, and biomarker/target discovery.
“By providing tools for antibody design, molecular property analysis, and three-dimensional interaction simulation, Converge Bio aims to drive innovation and accelerate the pace of bringing novel drugs to market,” said CEO and co-founder Dov Gertz.
Source: TechCrunch